AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 11 min read$PGEN

Sabzevari Helen sold $2.0M of PGEN

Sabzevari Helen (President and CEO) sold 346,836 shares of PRECIGEN, INC. (PGEN) at $5.89 ($2.04M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sabzevari Helen
Published Jul 1, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
high confidence
Mentioned
$PGEN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market sale size, price, and post-transaction holdings, but the 10b5-1 designation reduces interpretive weight.

02

Market read

This can marginally influence short-term sentiment/positioning, but it does not introduce new fundamentals in the provided text.

03

What to watch

Traders may over-weight insider sales; without changes to guidance, trial results, or financing terms, the filing is unlikely to reset valuation assumptions.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction disclosure for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

$PGENNeutralHigh confidence
Context

Precigen CEO Sabzevari Helen filed a Form 4 open-market sale of 346,836 shares at $5.89 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The disclosure is an open-market sale by the CEO, explicitly under a pre-arranged 10b5-1 plan, with no accompanying new operational/regulatory/financial catalyst in the text.

Market effects

Sector

Minimal; this is company-specific insider transaction data with no sector-wide regulatory/clinical/financing signal provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may be purely mechanical rather than a bearish view on fundamentals.

Key entities

  • issuer
    PRECIGEN, INC.

    Company whose CEO insider transaction is disclosed on Form 4.

  • insider
    Sabzevari Helen

    President and CEO who sold 346,836 shares at $5.8900/share.

Read at source← All news

Related articles

AUG 4
$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

SEC EDGAR 8-K6 min
JUN 1
$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

newswise.com4 min
MAY 30
$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e

prnewswire.com4 min